ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2182

PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Abstract Number: 2175

Pediatric Rheumatology Clinic Referral Patterns at a Large Midwestern Center
Abstract Number: 2195

Pediatric Rheumatology Graduation: A One-Way Bridge to Adult Care?
Abstract Number: 1897

People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective
Abstract Number: 0892

Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR
Abstract Number: 1405

Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis
Abstract Number: 1001

Perceived Mistreatment in Patients with Rheumatic Diseases: The Impact of the Underlying Diagnosis
Abstract Number: 2384

Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus
Abstract Number: 1015

Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Abstract Number: 1724

Performance of a Novel Cardiovascular Risk Calculator in Rheumatoid Arthritis
Abstract Number: L04

Performance of an Artificial Intelligence Model Compared to Multiple Human Experts in Scoring Synovitis Severity and Osteophyte Severity on Joint Ultrasound Images
Abstract Number: 1438

Performance of Combined MRI SI Joint Active and Structural Lesions in Diagnosing Axial SpA: A Prospective Cohort Study
Abstract Number: 1740

Performance of Large Language Models in Rheumatology Board-Like Questions: Accuracy, Quality, and Safety
Abstract Number: 0118

Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Abstract Number: 2444

Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].